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Nicotine Inhibits Cardiac Apoptosis
Induced by Lipopolysaccharide in Rats
Jun Suzuki, MD, PHD, Evelyn Bayna, PHD, Erminia Dalle Molle, Wilbur Y. W. Lew, MD, FACC
San Diego, California
OBJECTIVES Apoptosis develops in several heart diseases, but the therapeutic options are limited. It was
hypothesized that nicotine, which inhibits apoptosis in several cells, inhibits cardiac apoptosis
induced by lipopolysaccharide (LPS).
BACKGROUND Over-the-counter nicotine produces sustained levels (10 to 25 ng/ml) that may be antiapop-
totic. Low levels of LPS induce apoptosis by activating tissue renin-angiotensin to stimulate
angiotensin II, type 1 (AT1) receptors in cardiac myocytes.
METHODS Adult Sprague Dawley rats were pretreated with nicotine (6 mg/kg/day) or saline for seven
to ten days (miniosmotic pumps). The LPS (1 mg/kg) was injected intravenously. Toll-like
receptor 4 (TLR4) and angiotensinogen messenger ribonucleic acid (mRNA) were measured
in the heart after 0, 4, 8, 16, and 24 h. Cardiac apoptosis was measured by terminal
deoxy-nucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) staining after
24 h. In vitro effects of LPS (10 ng/ml, 24 h) were studied in cardiac myocytes isolated from
rats pretreated with nicotine for 7 to 10 days, or after pre-exposing myocytes to nicotine (15
ng/ml) for 1, 4, 16, or 24 h.
RESULTS Neither nicotine nor LPS affected systolic blood pressure. The LPS increased cardiac
apoptosis after 24 h in saline-treated, but not nicotine-treated rats, despite similar increases
in cardiac TLR4 and angiotensinogen mRNA over 8 to 16 h. The LPS-induced apoptosis
was blocked by pre-exposing myocytes to nicotine for 4 to 24 h (partial inhibition after 1 h).
Nicotine did not inhibit apoptosis induced by angiotensin II (100 nM, 24 h).
CONCLUSIONS Therapeutic levels of nicotine inhibit LPS-induced cardiac apoptosis. This occurs after LPS
increases TLR4 and angiotensinogen mRNA, but proximal to AT1 receptor activation.
Nicotine may be a novel inhibitor of cardiac apoptosis in conditions associated with
circulating LPS (e.g., decompensated heart failure, acute and chronic infections). (J Am
Coll Cardiol 2003;41:482–8) © 2003 by the American College of Cardiology Foundation
Nicotine inhibits apoptosis in several cells induced by
diverse stimuli (1–5). This may have adverse effects since
apoptosis normally removes excessive or potentially danger-
ous cells (e.g., predispose to cancer in smokers). This effect
of nicotine may be advantageous in the heart, where
apoptosis is undesirable. Cardiac myocytes are terminally
differentiated cells with a limited (but not absent [6])
capacity to regenerate. Cardiac apoptosis is increased in
multiple forms of heart failure and may contribute to the
progression of disease (7). The therapeutic options for
inhibiting apoptosis in heart disease are limited. It is
unknown if nicotine has antiapoptotic effects on cardiac
cells. The therapeutic use of nicotine for inhibiting apopto-
sis has not been previously investigated.
See page 497
It was hypothesized that therapeutic levels of nicotine
inhibit cardiac apoptosis induced by lipopolysaccharide
(LPS). The LPS from gram-negative bacteria induces
cardiac apoptosis in sepsis (8,9). Low levels of LPS also
induce cardiac apoptosis (10). We found that a single dose
of LPS that causes no distress and does not affect blood
pressure is sufficient to increase cardiac apoptosis for days
(10). The heart is sensitive to LPS because of abundant
expression of the LPS receptor, toll-like receptor 4 (TLR4),
on cardiac myocytes (11). This has important implications
since plasma LPS levels in pg/ml to low ng/ml range occur
in several conditions (12), including decompensated heart
failure (13), chronic infections (14), and periodontitis (15).
Inhibiting cardiac apoptosis may minimize injury to the
heart as an innocent bystander in these common conditions.
Nicotine may be a novel therapy to inhibit cardiac
apoptosis. Nicotine is a safe, over-the-counter medication
used in smoking cessation and to treat ulcerative colitis,
Alzheimer’s disease, Parkinson’s disease, and Tourette’s
syndrome (16,17). Nicotine patches and gum produce
sustained blood nicotine levels of 10 to 25 ng/ml for over
24 h (17). Although nicotine has adverse cardiovascular
effects when combined with cardiotoxic substances in smok-
ing (18), nicotine can be used safely as a medication even in
patients with cardiac disease (18–20).
This study examines if therapeutic levels of nicotine
inhibit cardiac apoptosis using in vivo and in vitro models of
LPS (10). Rats were exposed to nicotine for one week with
miniosmotic pumps, or isolated cardiac myocytes were
exposed to nicotine in vitro using levels comparable to those
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achieved with commercially available preparations (e.g.,
nicotine gum and transdermal patches) (17). The results
from this study may expand the therapeutic uses of nicotine
(16) to include inhibition of LPS-induced cardiac apoptosis.
METHODS
Experiments were performed in accordance with institu-
tional guidelines and the National Institutes of Health
Guide for the Care and Use of Laboratory Animals. Systolic
blood pressure was measured by tail cuff in adult Sprague
Dawley rats (250 to 400 g, either gender). Rats were
anesthetized with ketamine (100 mg/kg intramuscularly)
and xylazine (8 mg/kg intramuscularly) to implant Alzet
miniosmotic pumps (model 2002, Alza Corp., Mountain
View, California) subcutaneously through 1 to 2 cm inci-
sions under sterile conditions. The pumps were filled with
saline or nicotine dihydrochloride to infuse solution at 0.5
l/h, with delivery of nicotine at 6 mg/kg/day (21). The rats
were allowed to recover for one week to ensure full recovery
from anesthesia, surgery, and to allow complete wound
healing. This minimized the risk of systemic exposure to
bacteria from the wound site, which may induce LPS
tolerance in the heart (22). After 7 to 10 days, 1 mg/kg LPS
(Escherichia coli 055, LPS no. B5, lot 2039F, List Biological
Laboratories, Cambell, California) or vehicle (saline) were
injected into the tail vein. This dose of LPS does not alter
blood pressure (10) and in a preliminary study, heart rate
and left ventricular function (measured by echocardiogra-
phy) were unaffected at 24 h (23). Rats were euthanized
24 h after injections; the heart was excised and fixed in 3.7%
formaldehyde solution for 24 h. The heart was embedded in
paraffin and then sliced with 5 m cross-sections mounted
onto glass slides.
Apoptosis was measured by terminal deoxy-nucleotidyl
transferase-mediated dUTP nick end-labeling (TUNEL)
staining of heart slices using CardioTACS In Situ Apopto-
sis Detection kit (R&D Systems, Minneapolis, Minnesota),
as recently described (10). In brief, six to eight digital
photomicrographs of transmural sections of the left ventric-
ular anterior free wall were computer processed with NIH
Image. Each photomicrograph sampled an area of approx-
imately 7,500 m2. On average, we measured a total of
approximately 100,000 nuclei from each heart. The number
of TUNEL stained nuclei within myocytes were compared
with the total number of nuclei in a nuclease pretreated
section from the same region. The average transmural
density of nuclei (nuclei per m2) and TUNEL positive
stained nuclei per m2 were calculated from each section to
determine the rate of TUNEL positive nuclei per 106 nuclei
(10).
In vitro studies were performed in isolated cardiac myo-
cytes as described previously (10). In brief, rats were
anesthetized with sodium pentobarbital (40 mg/kg intra-
peritoneal), the heart was excised and perfused with 15 to 30
mg/kg depyrogenated collagenase B and protease that con-
tained 0.3 to 0.5 ng/ml LPS (measured by Limulus
amobocyte lysate test QCL-1000, BioWhittaker, Walkers-
ville, Maryland) (22). Enyzme depyrogenation removed
99.9% of the LPS contaminants to minimize induction of
LPS tolerance in isolated myocytes. Myocytes were plated
on dishes precoated with laminin and stored at 37°C in 5%
CO2 in a Dulbeccos modified Eagle’s media (10).
Cardiac myocytes were incubated with LPS (10 ng/ml)
and/or angiotensin II (Ang II) (100 nM) for 16 to 24 h.
Cardiac myocytes were fixed with 4% formalin phosphate
buffered saline for TUNEL assays with over 2,000 cells
scored for each group. In protocols examining nicotine in
vitro, cardiac myocytes were preincubated with nicotine
(15 ng/ml) or vehicle for 1 to 24 h, prior to LPS (10 ng/ml)
exposure for an additional 24 h.
Cardiac levels of TLR4 and angiotensinogen messenger
ribonucleic acid (mRNA) were measured from heart sec-
tions placed in RNAlater (Qiagen, Inc., Valencia, Califor-
nia) to preserve ribonucleic acid (RNA) integrity and stored
at 70°C. Total RNA was isolated with TRIzol reagent
according to the manufacturer’s protocol (Life Technolo-
gies, Rockville, Maryland). The RNA was treated with
RNase free DNase I (Roche Molecular Biochemicals, In-
dianapolis, Indiana), precipitated and 10 g used for first
strand complementary deoxyribonucleic acid (cDNA) syn-
thesis with SuperScript II reverse transcriptase (Life Tech-
nologies).
The relative levels of TLR4 and angiotensinogen mRNA
were measured with a Perkin-Elmer ABI Prism 7700 and
Sequence Detection System software (Foster City, Califor-
nia). Equal amounts of cDNA were used in duplicate and
amplified with the Taqman Master Mix provided by
Perkin-Elmer. The sequences used for the rat angiotensino-
gen were from GenBank Accession # L00090, exon 5,
nucleotides 157 to 176, 213 to 235, forward and reverse
primers, respectively, and 178 to 202 for the probe. The rat
TLR4 sequences were from Accession #AF057025, nucle-
otides 2107 to 2131, 2158 to 2177, and 2133 to 2156 as
above. Amplification efficiencies were validated and normal-
ized against 18S ribosomal RNA and relative increases were
calculated using the Standard Curve Method for quantita-
tion (Ref: ABI Prism 7700 SDS User Bulletin #2 P/N
4303859 Rev. A).
Abbreviations and Acronyms
Ang II  angiotensin II
ANOVA  analysis of variance
AT1  angiotensin II receptor, type 1
cDNA  complementary deoxyribonucleic acid
LPS  lipopolysaccharide
mRNA  messenger ribonucleic acid
nAchR  nicotinic receptor for acetylcholine
RNA  ribonucleic acid
TLR4  toll-like receptor 4
TUNEL  terminal deoxy-nucleotidyl transferase-
mediated dUTP nick end-labeling
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Statistical analyses were performed with one- or two-way
analysis of variance (ANOVA) to compare results from
different rats. One- or two-way repeated measures ANOVA
were used when myocytes from the same rat underwent
different treatments. Posthoc comparisons were performed
by Student-Newman-Keuls methods. Results are presented
as mean  SE with p  0.05 used to indicate statistical
significance.
RESULTS
Miniosmotic pumps delivered nicotine (6 mg/kg/day) or
saline in vivo to rats (n  12 each) for 7 to 10 days. In pilot
studies, three rats treated with nicotine-filled pumps had
blood nicotine levels of 21, 30, and 52 ng/ml, while nicotine
was nondetectable in three rats treated with saline-loaded
pumps. Systolic blood pressure (tail cuff) did not change two
days or one week after implanting the pumps (Table 1).
After one week of pretreatment, LPS (1 mg/kg) or vehicle
was injected into the tail vein of rats with saline pumps (six
rats in the saline-vehicle or control group, six rats in the
saline-LPS group) and nicotine-filled pumps (five rats in
the nicotine-vehicle group, seven rats in the nicotine-LPS
group). None of the rats developed any signs of distress or
change in systolic blood pressure over the ensuing 24 h
(Table 1).
Figure 1 shows TUNEL staining in the left ventricle 24 h
after LPS or vehicle injections. The rate of TUNEL positive
stained nuclei per 106 nuclei was calculated based on
sampling approximately 105 nuclei from each heart. The
LPS increased positive TUNEL stained nuclei in rats
pretreated with saline-filled pumps (saline-LPS compared
with saline-vehicle), but not in rats pretreated with
nicotine-filled pumps (nicotine-LPS compared with
nicotine-vehicle) (p  0.05, two-way ANOVA, p  0.01
for interaction between nicotine and LPS, posthoc analysis
with multiple comparison procedures by Student-Newman-
Keuls method). Thus, 7 to 10 days of nicotine exposure
blocked cardiac apoptosis induced by LPS in vivo.
Since LPS activates multiple cells to release a myriad of
endogenous mediators in vivo, the direct cardiac effects of
LPS can be discerned with isolated cardiac myocytes ex-
posed to LPS in vitro (10). Cardiac myocytes isolated from
rats after seven to ten days of nicotine (6 mg/kg/day) or
saline infusions were exposed to LPS (10 ng/ml) or vehicle
in vitro for 24 h. Figure 2 shows that LPS in vitro had
similar effects as LPS in vivo. The LPS increased TUNEL
staining in myocytes from saline-treated rats, but not in
myocytes from nicotine-treated rats (p  0.05, n  13,
two-way repeated measures ANOVA, p  0.001 for inter-
action between nicotine and LPS, posthoc analysis with
multiple comparison procedures by Student-Newman-
Keuls method).
Cardiac myocytes are activated by LPS through the LPS
receptor, TLR4 (11) and cardiac renin-angiotensin induces
apoptosis through angiotensin II receptor, type 1 (AT1)
receptors (10). The time course for LPS (1 mg/kg intrave-
Table 1. Systolic Blood Pressure
Time
Control
(Saline-vehicle)
LPS
(Saline-LPS)
Nicotine
(Nicotine-vehicle)
Nicotine-LPS
(Nicotine-LPS)
1 week (before pump) 126  5 122  2 125  2 123  1
5 days (2 days after pump) 127  5 122  2 126  2 122  2
Baseline  0 (1 week after pump) 122  3 121  2 128  0 124  1
15 min 128  3 119  2 122  2 124  2
30 min n/a 121  1 n/a 125  2
45 min n/a 121  1 n/a 124  0
1 h 125  4 119  2 n/a 123  2
2 h 128  3 121  1 122  2 124  2
4 h n/a 119  3 n/a 129  3
24 h 124  2 120  2 128  2 126  2
Systolic blood pressure (mm Hg, mean  SE) measured in four groups of rats before, 2 days and 1 week after implanting
miniosmotic pumps to deliver nicotine (6 mg/kg/day) or saline. After 1 week of pretreatment (baseline time  0), blood pressure
before and after injecting lipopolysaccharide (LPS) (1 mg/kg) or vehicle into the tail vein (n/a  not applicable, not measured).
There was no change in systolic blood pressure in any group at any time after any intervention (p  ns, one-way repeated
measures analysis of variance).
Figure 1. Terminal deoxy-nucleotidyl transferase-mediated dUTP nick
end-labeling (TUNEL) staining in the left ventricle (mean SE, n 5 to
7) of rats pretreated for 7 to 10 days with nicotine (6 mg/kg/day) versus
saline (miniosmotic pump) and then injected with intravenous lipopoly-
saccharide (LPS) (1 mg/kg) versus vehicle. After 24 h, LPS increased
TUNEL staining in saline pretreated rats (*p 0.05, saline-LPS compared
with other three groups).
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nously) to activate TLR4 and angiotensinogen (precursor of
angiotensin I) mRNA in the heart was measured in rats
pretreated with 7 to 10 days of nicotine (6 mg/kg/day) or
saline. Figure 3 shows that LPS increased cardiac TLR4
mRNA over 8 to 16 h (p  0.05 compared with 0, 4, or
24 h, post-hoc comparisons by Student-Newman-Keuls
method), with no difference in response between nicotine
and saline-treated rats (p  0.83 for nicotine vs. saline
pump, two-way ANOVA). Figure 4 demonstrates increased
cardiac angiotensinogen mRNA 8 h after LPS (p  0.05
compared with 24 h, posthoc comparisons by Student-
Newman-Keuls method), with no difference between nico-
tine and saline-treated rats (p  0.89 for nicotine vs. saline,
two-way ANOVA). Thus, nicotine does not decrease the
sensitivity of cardiac myocytes to respond to LPS or events
leading up to the activation of angiotensinogen mRNA.
Since LPS induces apoptosis by activating cardiac AT1
receptors (10), the response to LPS (10 ng/ml, 24 h) and
Ang II (100 nM, 24 h) were compared in cardiac myocytes
isolated from nicotine and saline-exposed rats. In Figure 5,
both LPS and Ang II increased TUNEL staining compared
with vehicle in myocytes from saline-treated rats (p  0.05,
one-way repeated measures ANOVA, n  10, posthoc
comparisons by Student-Newman-Keuls method). In myo-
cytes from nicotine treated rats, only Ang II and not LPS
increased TUNEL staining (p  0.01, n  11, posthoc
comparisons by Student-Newman-Keuls method). Thus,
nicotine inhibited LPS-induced apoptosis proximal to the
activation of AT1 receptors in cardiac myocytes.
The antiapoptotic effects of nicotine in vivo may be due to
direct effects on cardiac myocytes (which are not known to
possess nicotinic receptors) or secondary to nicotine activa-
tion of noncardiac cells. To address this issue, cardiac
myocytes isolated from naı¨ve animals (without miniosmotic
pumps) were exposed to nicotine in vitro (15 ng/ml) for 1 h,
and then treated with LPS (10 ng/ml) or vehicle for another
Figure 2. Terminal deoxy-nucleotidyl transferase-mediated dUTP nick
end-labeling (TUNEL) staining (mean SE, n 13) in cardiac myocytes
isolated from rats pretreated for 7 to 10 days with nicotine (6 mg/kg/day)
versus saline, and then exposed to lipopolysaccharide (LPS) (10 ng/ml)
versus vehicle for 24 h. The LPS increased TUNEL staining in myocytes
from saline pretreated rats (*p  0.05, saline-LPS compared with other
three groups).
Figure 3. Toll-like receptor 4 (TLR4) messenger ribonucleic acid
(mRNA) (normalized to 18 S ribosomal ribonucleic acid [rRNA]; mean 
SE, n  4 to 6) in the heart after lipopolysaccharide (LPS) (1 mg/kg
intravenously) injected into rats pretreated for 7 to 10 days with nicotine (6
mg/kg/day) versus saline. Toll-like receptor 4 mRNA increased at 8 to 16 h
(*p  0.05) with no difference between nicotine and saline pretreated rats.
Open bar  saline; closed bar  nicotine.
Figure 4. Angiotensinogen messenger ribonucleic acid (mRNA) (normal-
ized to 18 S ribosomal ribonucleic acid [rRNA]; mean  SE, n  4 to 6)
in the heart after lipopolysaccharide (LPS) (1 mg/kg intravenously)
injected into rats pretreated for 7 to 10 days with nicotine (6 mg/kg/day)
versus saline. Angiotensinogen mRNA increased at 8 h (*p  0.05), with
no difference between nicotine and saline pretreated rats. Open bar 
saline; closed bar  nicotine.
Figure 5. Terminal deoxy-nucleotidyl transferase-mediated dUTP nick
end-labeling (TUNEL) staining (mean  SE, n  10 to 11) in cardiac
myocytes isolated from rats pretreated for 7 to 10 days with nicotine (6
mg/kg/day) versus vehicle. In myocytes from saline-pretreated rats,
TUNEL staining increased 24 h after lipopolysaccharide (LPS) (10 ng/ml)
or angiotensin II (Ang II) (100 nM) compared with vehicle, but only Ang
II had an effect in myocytes from nicotine-pretreated rats (*p  0.05).
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24 h. Figure 6 demonstrates that pretreatment with nicotine
in vitro attenuated, but did not abolish LPS-induced apo-
ptosis. The LPS increased TUNEL staining in myocytes
pretreated with nicotine for 1 h, but not as great as in
myocytes pretreated with saline (p  0.05, two-way re-
peated measures ANOVA, posthoc comparisons by
Student-Newman-Keuls method). Thus, nicotine has some
direct antiapoptotic effects on cardiac myocytes within 1 h.
The time course for direct, antiapoptotic effects of nico-
tine was examined in cardiac myocytes exposed to nicotine
(15 ng/ml) or saline in vitro for 4, 16, or 24 h, prior to
exposure to LPS (10 ng/ml) or vehicle for an additional
24 h. The results are shown in Table 2. The LPS increased
TUNEL staining in myocytes pretreated with saline, but
not in myocytes exposed before to nicotine in vitro for 4, 16,
or 24 h (p  0.05 for nicotine effects and nicotine interac-
tion with LPS, two-way repeated measures ANOVA,
posthoc comparisons by Student-Newman-Keuls method).
Thus, the antiapoptotic effects of nicotine in vitro were
similar to those of nicotine in vivo.
DISCUSSION
This study demonstrates that therapeutic levels of nicotine
inhibit cardiac apoptosis induced by LPS. Nicotine has
direct antiapoptotic effects on cardiac myocytes since nico-
tine exposure in vitro for 4 to 24 h was as effective as in vivo
exposure for 7 to 10 days. The antiapoptotic effects of
nicotine develop within 1 h, are complete after 4 h, and
occur with nicotine levels (15 ng/ml in vitro, 20 to 50 ng/ml
in vivo) comparable to those achieved with over-the-counter
preparations (17). These results demonstrate a novel thera-
peutic use for nicotine to inhibit cardiac apoptosis.
Nicotine did not nonspecifically decrease the response of
cardiac myocytes to LPS. Initial steps in LPS-induced
activation, including the increase in cardiac TLR4 (LPS
receptor) and angiotensinogen mRNA were unaffected by 7
to 10 days of nicotine exposure. Nicotine does not inhibit
Ang II induced apoptosis, a key step in LPS-induced
apoptosis (10). These data indicate that nicotine inhibits
LPS activation of cardiac renin-angiotensin (distal to an-
giotensinogen mRNA, but proximal to the activation of
AT1 receptors) in myocytes to inhibit apoptosis. Further
investigation into the effects of nicotine on the signaling
pathways and transcription factors of LPS activated TLR4
are required to elucidate the mechanism of nicotine inhibi-
tion during LPS induced cardiac myocyte apoptosis.
These results raise the possibility that nicotine may
inhibit apoptosis in other models involving cardiac renin-
angiotensin. For example, cardiac apoptosis is induced by
local renin-angiotensin activation with stretch of cardiac
myocytes (24) in rat models of spontaneous hypertension
(25–27) and diabetic cardiomyopathy (28). Patients with
essential hypertension have increased cardiac apoptosis that
is attenuated by an AT1 receptor blocker (29). Future
studies are needed to determine if nicotine inhibits apopto-
sis in these conditions.
The direct cardiac effects of nicotine are intriguing, since
cardiac myocytes are not known to possess nicotinic recep-
tors. Nicotinic receptors for acetylcholine (nAchRs) are a
large family of transmembrane proteins with a pentameric
structure (30). In the heart, nAchRs are localized primarily
in postganglionic neurons of autonomic nerves (18). In
neuronal cells, nicotine (e.g., 10 M) inhibits apoptosis by
Figure 6. Terminal deoxy-nucleotidyl transferase-mediated dUTP nick
end-labeling (TUNEL) staining (mean SE, n 10) in cardiac myocytes
pretreated for 1 h with nicotine (15 ng/ml) versus saline. After 24 h,
lipopolysaccharide (LPS) (10 ng/ml) increased TUNEL staining (*p 
0.05). This was attenuated, but not abolished by pretreatment of myocytes
with nicotine for 1 h (p  0.05).
Table 2. TUNEL Staining in Isolated Cardiac Myocytes
Pretreatment
Time
Control
(Saline-vehicle)
LPS
(Saline-LPS)
Nicotine
(Nicotine-vehicle)
Nicotine-LPS
(Nicotine-LPS)
1 h (n  10) 3.3  0.5% 5.7  0.8%* 2.9  0.4% 4.7  0.5%†
4 h (n  10) 2.6  0.4% 4.0  0.4%* 2.8  0.3% 3.0  0.4%
16 h (n  6) 3.4  0.3% 4.7  0.5%* 3.7  0.6% 3.0  0.5%
24 h (n  4) 3.0  0.9% 4.8  1.1%* 3.2  0.9% 2.9  1.0%
Percent terminal deoxy-nucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) positive staining (mean  SE) in
cardiac myocytes pretreated with saline or nicotine (15 ng/ml) for 1 to 24 h, and then treated with vehicle or lipopolysaccharide
(LPS) (10 ng/ml) for an additional 24 hs. Lipopolysaccharide increased TUNEL staining in myocytes pretreated with saline,
which was completely blocked by 4 to 24 h of nicotine pretreatment (*p 0.05 for LPS group compared with other three groups,
two-way repeated measures analysis of variance; posthoc comparisons by Student-Newman-Keuls method). One hour of nicotine
pretreatment attenuated, but did not completely abolish LPS effects (†p  0.05 for Nicotine-LPS group compared with other
three groups).
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activating nAchR (2,31). However, nicotine also inhibits
apoptosis by nonreceptor-mediated mechanisms in several
cells with an inhibitory concentration of drug with 50% of
maximum effectiveness (IC50) 50 to 100 M nicotine (1).
Low M levels of nicotine inhibit apoptosis in human (32)
and cancer cell lines (5,33) and regulate several apoptotic
genes in endothelial cells (34). It is unknown if low levels of
nicotine (15 ng/ml  92 nM) inhibit LPS-induced apopto-
sis in cardiac myocytes by a nonreceptor or nAchR-
mediated mechanism.
Nicotine has non–nAChR-mediated effects on cardiac
fibroblasts (35), sinoatrial node cells (36), and ventricular
myocytes. Nicotine (10 nM to 100 M) inhibits transient
outward (Ito, IC50 40 nM nicotine) and inward rectifier
(IK1) potassium currents and lengthens action potential
duration in ventricular myocytes (37,38). This is not re-
versed by nAChR antagonist (mecamylamine), muscarinic
acetylcholine receptor antagonist (atropine), or a beta-
adrenergic receptor blocker indicating a direct effect of
nicotine on ion channels (38). Thus, low levels of nicotine
may have direct effects on cardiac myocytes, independently
of nicotinic receptors.
Nicotine has been used therapeutically (e.g., in ulcerative
colitis and smoking cessation programs) (16) with nicotine
gum and transdermal patches producing sustained blood
nicotine levels of 10 to 25 mg/ml for hours (17,18). Nicotine
has a 2 to 3 h elimination half-life, with a 20 h terminal
half-life as nicotine is released from body tissues (16).
Cotinine, the major metabolite of nicotine, has a 16-h
half-life. Cotinine also inhibits apoptosis (1). Since nicotine
is safe even in patients with cardiac disease (18–20),
over-the-counter preparations may be useful to produce
nicotine levels that effectively inhibit LPS-induced cardiac
apoptosis.
These results may be applicable in conditions associated
with circulating LPS. Inhibiting apoptosis may attenuate
myocyte losses in sepsis (8,9). In patients with decompen-
sated heart failure, elevated plasma LPS levels (13) may
induce apoptosis and contribute to further cardiac damage.
The LPS is elevated in patients with cirrhosis, pancreatitis,
hemodialysis (12), abdominal surgery (39), cardiopulmonary
bypass surgery (40), and colonoscopy (41). Nicotine may
provide a convenient therapy to protect the heart from
apoptosis during transient elevations in LPS in these con-
ditions and procedures.
Periodontitis may be an important source of systemic
LPS. Elevated LPS levels occur with oral procedures (e.g.,
scaling) or mastication in patients with severe periodontal
disease (15). This produces systemic inflammatory effects
with elevated levels of C-reactive protein directly related to
the severity of periodontitis (42,43). Chronic systemic
effects develop, as periodontal disease has been associated
with increased carotid artery intima-media wall thickness in
the Atherosclerosis Risk In Communities (ARIC) study
(44). Since LPS induces cardiac apoptosis, recurrent epi-
sodes of subclinical exposure to LPS may have significant
cumulative effects. Nicotine may prevent cardiac apoptosis
in this common clinical condition.
In summary, nicotine inhibits LPS-induced cardiac apo-
ptosis. Nicotine has direct effects on cardiac myocytes to
inhibit apoptosis within an hour (complete inhibition after
4 h) with nicotine levels comparable to those achieved with
over-the-counter preparations. Nicotine inhibits LPS acti-
vation of cardiac angiotensin, which stimulates AT1 recep-
tors in myocytes. Nicotine may be a novel therapy to inhibit
cardiac apoptosis during periods of increased susceptibility
with exposure to LPS.
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